Loading, Please Wait...
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York, NY.
Ms. Johnson will present an overview of Daré and provide an update on the Company’s lead clinical programs: Ovaprene®, a potential first-in-category hormone-free, monthly contraceptive solution; DARE-BV1, a novel solution-to-gel formulation containing clindamycin phosphate 2%, an antibiotic used to treat bacterial infections; and Sildenafil Cream, 3.6%, a novel topical cream formulation of sildenafil, the active ingredient in Viagra®, for the potential treatment of female sexual arousal disorder (FSAD).
Details of the presentation follow:
Event: H.C. Wainwright 21st Annual Global Investment Conference
Date: Monday, September 9, 2019
Time: 8:20 a.m. EDT
A live webcast of the presentation will be available via the Investors section of the Company’s website at https://ir.darebioscience.com/events-presentations. An archive of the presentation will be available on the website for 10 business days.
Investors attending the conference who are interested in meeting with Ms. Johnson should contact their H.C. Wainwright representative to make arrangements.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of the company's website mentioned above.
Investors on behalf of Daré Bioscience, Inc.:
Media on behalf of Daré Bioscience, Inc.:
Source: Daré Bioscience